Antibody-drug conjugates (ADCs) are transforming oncology drug development by enabling targeted delivery of potent therapeutics. Crown Bioscience leverages complementary preclinical models—organoids and patient-derived xenografts (PDXs)—to accelerate ADC research and improve translational relevance. Organoids provide high-throughput, human-relevant platforms for biomarker discovery and screening across diverse tumor types. PDX models offer in vivo validation and efficacy insights within an intact tumor microenvironment. Together, these platforms support comprehensive ADC evaluation, from target selection to therapeutic response. This presentation highlights how integrating organoid and PDX technologies enhances ADC development, enabling better prediction of clinical outcomes and guiding data-driven decisions in oncology pipelines.